这项研究旨在评估粘膜瘘再喂养(MFR)是否安全且有益于肠造口术早产儿的生长和肠道适应。
这项探索性随机对照试验招募了妊娠35周前出生并进行肠造口术的婴儿。如果造口输出量≥40毫升/千克/天,婴儿被分配到高输出MFR组,并接受MFR.如果造口输出<40mL/kg/天,将婴儿随机分为正常输出MFR组或对照组.增长,血清瓜氨酸水平,并比较肠径。评估MFR的安全性。
包括20名婴儿。增长率大幅度上升,MFR后结肠直径明显较大。然而,正常输出MFR组和对照组的瓜氨酸水平无显著差异.1例肠穿孔发生在人工复位造口脱垂过程中。尽管与MFR的关联尚不清楚,我们记录了2例MFR期间培养证实的脓毒症.
MFR有利于肠造口术早产儿的生长和肠道适应,可以通过标准化方案安全实施。然而,感染性并发症需要进一步调查.
clinicaltrials.govNCT02812095,2016年6月6日回顾性注册。
This study aimed to evaluate whether mucous fistula refeeding (MFR) is safe and beneficial for the growth and intestinal adaptation of preterm infants with enterostomies.
This exploratory randomized controlled trial enrolled infants born before 35 weeks\' gestation with enterostomy. If the stomal output was ≥ 40 mL/kg/day, infants were assigned to the high-output MFR group and received MFR. If the stoma output was < 40 mL/kg/day, infants were randomized to the normal-output MFR group or the control group. Growth, serum citrulline levels, and bowel diameter in loopograms were compared. The safety of MFR was evaluated.
Twenty infants were included. The growth rate increased considerably, and the colon diameter was significantly larger after MFR. However, the citrulline levels did not significantly differ between the normal-output MFR and the control group. One case of bowel perforation occurred during the manual reduction for stoma prolapse. Although the association with MFR was unclear, two cases of culture-proven sepsis during MFR were noted.
MFR benefits the growth and intestinal adaptation of preterm infants with enterostomy and can be safely implemented with a standardized protocol. However, infectious complications need to be investigated further.
clinicaltrials.gov NCT02812095, retrospectively registered on June 6, 2016.